triple-hormone-receptor agonist retatrutide for obesity - a phase 2 trial Triple hormone receptor metabolic dysfunction-associated steatotic liver disease: randomized 2a This phase 2 trial observed
Pay in 4 interest-free payments of $7.28 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Sep 6 - Sep 11




























